TLR9 and Arthritis: It has been clearly shown that pristane activates APCs priming autoreactive T cells, which induces a chronic arthritis development.32 Thus, we assume that the major effect of TLR9 inhibition is suppression of cytokine production and reduced activation of APCs, leading to reduction in inflammation and partial suppression of arthritogenic T cell responses.